^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KN5501

    i
    Other names: KN5501, Anti-CD19 CAR NK Cells
    Associations

    News

    Trials
    Company:
    Nanjing Enricnk Biotech
    Drug class:
    CD19 inhibitor, NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P1 trial
    |
    cyclophosphamide • KN5501
    4ms
    An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Changzhou No.2 People's Hospital | Initiation date: Mar 2024 --> Aug 2024
    Trial initiation date
    |
    cyclophosphamide • KN5501
    4ms
    An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=12, Recruiting, Changhai Hospital | Trial completion date: Aug 2026 --> Aug 2025 | Initiation date: Jul 2024 --> Aug 2023 | Trial primary completion date: Aug 2025 --> Aug 2024
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    cyclophosphamide • KN5501
    5ms
    An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy (clinicaltrials.gov)
    P1, N=36, Recruiting, Changhai Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • KN5501
    5ms
    An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=12, Recruiting, Changhai Hospital | Trial completion date: Aug 2025 --> Aug 2026 | Initiation date: Aug 2023 --> Jul 2024 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    cyclophosphamide • KN5501
    5ms
    An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Changhai Hospital
    New P1 trial
    |
    cyclophosphamide • KN5501
    almost2years
    The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Changhai Hospital
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • KN5501